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Background: Low-density lipoprotein (LDL) particle (P, or molar) concentration has been shown to be a more
sensitive marker of cardiovascular disease (CVD) risk than LDL cholesterol. Although elevated circulating
lipoprotein(a) [Lp(a)] cholesterol and mass have been associated with CV risk, no practicable method exists to
measure Lp(a)-P. We have developed a method of determining Lp(a)-P suitable for routine clinical use.
Methods: Lipoprotein immunoﬁxation electrophoresis (Lipo-IFE) involves rigidly controlled electrophoretic sep-
aration of serum lipoproteins, probingwith polyclonal apolipoprotein B antibodies, then visualization after stain-
ing with a nonspeciﬁc protein stain (Acid Violet). Lipo-IFE was compared to the Lp(a) mass assay for 1086
randomly selected patient samples, and for 254 samples stratiﬁed by apo(a) isoform size.
Results: The Lipo-IFE method was shown to be precise (CV b10% above the 50 nmol/l limit of quantitation) and
linear across a 16-fold range. Lipo-IFE compared well with the mass-based Lp(a) assay (r= 0.95), but was not
affected by variations in apo(a) isoform size. With a throughput of 100 samples in 90 min, the assay is suitable
for use in the clinical laboratory.
Conclusions: The Lipo-IFEmethodwill allow Lp(a)-P to be readily tested as a CVD risk factor in large-scale clinical
trials.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
It is well-established that increased serum concentrations of apoli-
poprotein B (apoB)-containing lipoproteins are associated with an
increased risk of developing cardiovascular disease (CVD) [1–5]. In par-
ticular, low density lipoproteins (LDL) and lipoprotein(a) [Lp(a)] are
signiﬁcant prognostic risk factors for future atherosclerotic disease
and associated adverse events [5–12]. Lp(a) is an LDL particle to
which apolipoprotein(a) [apo(a), a polypeptide comprised of multiple
loop domains called “kringles,” K] is covalently attached to apoB
(Fig. 1). It is the apo(a) portion that is thought to imbue the particle
with antiﬁbrinolytic properties owing to the structural similarity of
apo(a) to plasminogen [13]. Other proatherogenic properties are
thought to arise from the ability of Lp(a) to trafﬁc oxidized phospho-
lipids and induce inﬂammatory processes in the arterial intima [14],
which can lead to endothelial dysfunction, plaque development, andardiovascular disease; Lp(a),
ctrophoresis; K, kringle; SPIFE,
ediate density lipoprotein.
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. This is an open access article undersubsequent rupture. Indeed, loss-of-function variants in the LPA gene
that lower circulating Lp(a) levels have also been shown to confer pro-
tection from CVD [15]. Apo(a) consists of two kringle types—KIV, with
ten subtypes, and KV. Genetic variation in the length of the KIV type 2
(KIV-2) repeat region of apo(a) is largely responsible for the interindi-
vidual variability in Lp(a) size (i.e., molecular mass) [16,17] and, to
some extent, plasma Lp(a) levels [18]. These multiple molecular iso-
forms [which vary from about 300 to 800 kDa) [19]] have presented a
challenge for standardization of themeasurement of Lp(a)mass in plas-
ma [20–24], and variability in Lp(a) values obtained fromdifferentmea-
surement methods has also made it difﬁcult to interpret and compare
published data between clinical studies [25].
Over recent years, LDL particle (or more properly, molar) concentra-
tion (LDL-P, nmol/l) has beenproposed as amore robustmeasure of LDL
levels than LDL-cholesterol (LDL-C), owing to the fact that LDL particles
can carry variable amounts of cholesterol (and other lipids). Indeed,
LDL-C varies widely among individuals with the same LDL-P concentra-
tion [5–7]. Moreover, for individuals with discordant LDL-C and LDL-P
levels (i.e., increased for one metric but not the other), the LDL-
attributable CVD risk is better indicated by LDL-P [2,26]. Similar discor-
dance could theoretically apply to Lp(a)-P, owing to variations in
apo(a) mass as noted above.the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Fig. 1. Lp(a) particles of low and high molecular mass due to differences in apo(a) isoform size. Higher mass isoforms have more Kringle (K) IV-2 repeats than do lower mass isoforms.
Apo(a) with 6 (left) and 35 (right) KIV-2 repeats are shown here; 3 to 43 repeats have been reported [17], with resulting molecular masses varying from 300 to 800 kDa [16]. KIV-1
and KIV-3-10 and KV are identical in all apo(a) isoforms. Labels on the lower mass isoform apply to the high mass isoform as well.
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noassays to measure Lp(a)molar concentrations, but, if done properly
(i.e., with direct analysis of apo(a) mass), these methods are time-
consuming and labor-intensive [18,21,24]. Nuclear magnetic resonance
spectroscopy,which canmeasure LDL particle concentrations, cannot dis-
tinguish Lp(a) from other lipoprotein families. Some assays that measure
Lp(a) mass cannot distinguish between high and low molecular weight
apo(a) isoforms, and thus cannot be translated into Lp(a)-P concentra-
tions. There are antibodies against nonvariable epitopes of apo(a) (i.e., not
onKIV-2) that form thebasis for commonLp(a) assays that should, in the-
ory, be insensitive to variations in isoform mass [18], but turbidometric
assays utilizing this antibody might still be inﬂuenced by differences in
total particle mass [25]. Because of the inherent atherogenicity of
Lp(a) particles, being able to measure Lp(a)-P concentrations may have
important clinical utility, facilitating risk assessment and optimizing
lipid-modulating therapies [8,9]. To our knowledge, there are no Lp(a)-
P assays that are both isoform independent and suited for use in the
clinical laboratory. The purpose of this study was to utilize recent ad-
vances in electrophoretic methodologies, coupled with immunoﬁxation
detection, to develop and validate a novel, high-throughput, high-
sensitivity technique to determine serum Lp(a)-P concentrations.
2. Materials and methods
2.1. Sample treatment procedure
We analyzed serum samples submitted to Health Diagnostic Labora-
tory, Inc. IRB approval for studies using de-identiﬁed and aggregated
laboratory data was obtained from the Copernicus Group. At collection,
the blood samplewas drawn into an 8.5ml BDVacutainer® SST™ “Tiger
Top” serum-separator tube (Becton, Dickinson), immediately inverted
8–10 times, and allowed to clot for 30 min in an upright position.
After 15 min of centrifugation at 3000 rpm, the tube was then placed
in the biohazard bag provided with absorbent material, placed in the
refrigerator, and shipped to HDL, Inc. within 24 h. Serum samples
were kept at 4 °C and were analyzed within 4 days of collection. Lipo-
IFE (lipoprotein immunoﬁxation electrophoresis) was performed
using agarose electrophoresis [Serum Protein-IFE (SPIFE®) Helena
Laboratories, Beaumont, TX] followed by immunoﬁxation for apoB
(anti-apoB Goat pAb, CalBiochem), protein staining (Acid Violet), and
densitometric scanning (QuickScan 2000WIN V2 software). The proto-
col was a modiﬁcation of the SPIFE® Cholesterol-Vis System (Helena)[18]. Following electrophoresis, the gel blocks were removed and a
rigid antisera template was placed on the gel. The antibody was diluted
1:4with normal saline and administered through the template onto the
gel for 2 min. Excess antibody was removed by blotting and pressing.
Residual matrix antibody was removed by rehydration of the gel in a
tris-buffered saline bath for 1 min. These steps were performed three
times. The gel was subsequently dried at 56° for 8 min, then stained
with Acid Violet and scanned.
2.2. Quantiﬁcation of serum apoB and lipoprotein particles
Quantiﬁcation of serumapoBwas performed by immunoturbidimetry
(Roche Diagnostics). Areas under the Lipo-IFE tracing corresponding to
apoB-containing lipoproteins [very low and intermediate density lipo-
proteins (VLDL, IDL); LDL and Lp(a)] were converted into apoB concen-
trations and then into particle concentrations (nmol/l) based on the
following equation using Lp(a)-P as an example:
Lp að Þ Particle Number nmol
l
 
¼ Total Serum ApoB mg
dl
 
 Area % of Lp að Þ band 18:52
(The factor 18.52 was derived as follows: [ApoB (mg/dl) × 10 dl/
l × 106 nmol/mmol]/[molecular mass of apoB (540,000 mg/mmol)]
2.3. Accuracy, linearity, precision
The Lp(a)-P test accuracy (trueness) was determined by using Lipo-
IFE to measure Lp(a)-P concentrations in standards that had been pre-
assigned a concentration using a research immunoassay insensitive
to apo(a) polymorphisms (10 standards with a range of 50 to
400 nmol/l; kindly provided by S. Marcovina, Northwest LipidMetabolism
and Diabetes Research Laboratories) [18]. Linearity was assessed across a
range of 50 to 800 nmol/l by serial dilution. Precision was determined
using ﬁve serum samples run in 10 replicates (at 50 nmol/l and above)
on 20 separate gels, on 2 separate instruments over 3 days (i.e., 200
replicates of each of the ﬁve samples).
2.4. Speciﬁcity and interference
Speciﬁcity (i.e., insensitivity to apo(a) isoform size) was evaluated
by comparing the particle concentrations derived from two assays
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nonconjugated antibody (which was subsequently stained with Acid
Violet), and the other used an antibody conjugated with Alexa488 ﬂuo-
rescent tag (Life Technologies, Inc). Since the ﬂuorescent tag is directly
coordinated to the antibody, it does not require subsequent staining,
and is speciﬁc for apoB. Imageswere captured from theA-488 conjugate
using a ChemiDoc MP imaging system (Bio-Rad Laboratories). Both
methods were applied to 254 serum samples that had been classiﬁed
into three apo(a) isoform size categories: N700 kDa (large, n = 83),
600–700 kDa (intermediate, n= 105), and b600 kDa (small, n= 56),
respectively). Size categories were determined by Western blot via
Apolipoprotein(a) Isoform Analysis (AAISO) using the Novex®
WesternBreezeTM Chromogenic Western Blot Immunodetection Kit
(Invitrogen Life Technologies). It was envisaged that if the anti-apoB
method (which is, by deﬁnition, apo(a) isoform independent) and the
Acid Violet method (which is nonspeciﬁc and thus could be isoform
dependent) produced equivalent particle concentration values, then
the latter must be as isoform independent as the former, and the contri-
bution of variations in apo(a)mass (whichwould be variably stained by
Acid Violet) could be considered negligible. Lp(a)mass assayswere per-
formed using a commercially available immunoturbidimetric assay
(Denka Seiken Co. Ltd., Tokyo, Japan) [21]. Standard interference tests
were conducted (bilirubin, hemoglobin, and lipemia).
2.5. Statistical analysis
Comparisons between methods were made using Deming regres-
sion analysis. Slopes, intercepts, and Pearson correlations are reported.
3. Results
Lipo-IFE requires 1 μl of serum be applied to the gel; the void volume
for the test is 75 μl. In fasting samples, four lipoprotein classes can be
identiﬁed using this apoB immunoﬁxation approach: VLDL, IDL, LDL,
and Lp(a) (Fig. 2). As currently conﬁgured, 100 samples can be run on
a single gel (Supplementary Fig. 1). Although we have focused on
apoB here, the samples can also be probed for cholesterol and triglycer-
ides (Supplementary Fig. 1). The apoB-stained lipoprotein bands were
scanned (Supplementary Fig. 1) and, together with total serum apoB
values, used to calculate lipoprotein particle concentration for each
apoB-containing class.
3.1. Accuracy, linearity, precision
Determined in this manner, Lp(a)-P values were linear across the
tested range (r N 0.99; y= 1.05x− 36), and assay coefﬁcients of varia-
tionwere b10% at all Lp(a)-P levels of 50 nmol/l and above. Coefﬁcients
of variation ranging from 13 to 25% were associated with an Lp(a)-P
level of 40–50 nmol/l. Therefore, 50 nmol/l was considered the lower
limit of quantitation. The lower limit of detection was approximately
20 nmol/l; below a level of 20 nmol/l, an Lp(a) band could not consis-
tently be detected on the gel by visual inspection. Lp(a)-P values deter-
mined by Lipo-IFE correlated very well (r = 0.96) with those derived
from the research immunoassay in an analysis of 10 standard samples,Lp(a)
Chylomicron / 
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Fig. 2. Sample electrophoretogram stainedwith Acid Violet for apoB. LDL, low density lipoprote
lipoprotein(a). Anodic (+) and cathodic (−) poles are shown.analyzed in duplicate (Fig. 3). The correlation between the Lp(a) mass
and Lipo-IFE assays was 0.95 (p b 0.001) using 1086 random samples
(Fig. 4).
3.2. Speciﬁcity and interference
The sensitivity of the assay to apo(a) isoform size [apo(a) isoform
bias] was also addressed by analysis of 254 samples across a range of
isoform sizes using both Lipo-IFEwith the Alexa488-conjugated and un-
conjugated anti-apoB antibodies. The correlation between these two
particle-speciﬁc assays was 0.99; the slope of the regression line was
1.06, indicating that there was no signiﬁcant bias by apo(a) isoform
mass (Fig. 5). A subset of 114 of these samples were analyzed by West-
ern blot to determine apo(a) isoform size. The samples were grouped
into 3 molecular weight categories: 300–600 kDa (low), 600–700 kDa
(intermediate), and 700–800 kDa (high), and were analyzed by both
Lipo-IFE and the Lp(a) mass assay. The slopes of the individual regres-
sion lines for these three categories were 1.78, 1.21, and 0.77; and
their R values were 0.89, 0.96, and 0.77, respectively (Fig. 6), showing
an underrepresentation by the Lp(a) mass assay of the low molecular
mass apo(a) isoforms and an overrepresentation of the high molecular
mass apo(a) isoforms. The Lipo-IFE assay was not affected by standard
interferences including bilirubin up to 20 mg/dl, hemoglobin up to
500 mg/dl, or lipemia (triglycerides up to 500 mg/dl).
4. Discussion
The purpose of this report was to describe the development of a
novel quantitative electrophoresis-based assay for Lp(a)-P (Lipo-IFE)
suitable for routine clinical use. Our ﬁndings demonstrate that Lp(a)-P
can be measured with high sensitivity and accuracy using this method.
We have shown that the assay is linear, speciﬁc (i.e., isoform insensi-
tive), and precise.
A recent review of Lp(a) emphasized that, “Manufacturers of assays
for Lp(a) should seek to minimize the effects of apo(a) size on
Lp(a) levels.” [27] This is a problem that has always plagued mass-
based assays since a higher Lp(a) mass (i.e., total particle mass) could
mean more particles, higher mass isoforms apo(a), or larger lipid
cargo. An important feature of the present assay is its insensitivity to
variations in apo(a) isoform mass. This is in part because this assay
uses electrophoresis, not antibodies to apo(a), to isolate the lipoprotein
for apoB quantitation. This insensitivity was documented most directly
in the comparison between the Lp(a)-P and the apoB ﬂuorescence assay
(Fig. 5). It is perhaps surprising that an assay that uses a nonspeciﬁc pro-
tein stain like Acid Violet would not be inﬂuenced by differences in
apo(a) size, as the evidence presented here conﬁrms. It appears, there-
fore, that the anti-apoB antibodies (which are used to precipitate the li-
poproteins in the gel) add a very large amount of additional protein to
the particle, all of which is stained by Acid Violet. As a result, variations
in apo(a) size make a relatively small contribution to the total amount
of stainable protein associated with the Lp(a) particle, and hence do
not bias the assay. The ability to use an economical, nonspeciﬁc protein
stain (instead of expensive monoclonal antibodies) makes the current
method more suitable for use in the clinical laboratory.LDL
IDL
vLDL
ins; IDL, intermediate density lipoproteins; VLDL, very low density lipoproteins; and Lp(a),
Fig. 3. Lp(a) accuracy based on a comparison of Lipo-IFE Lp(a)-P with research immuno-
assay for Lp(a)-P (n=10measured twice; R= 0.97, p b 0.001). Light gray is line of iden-
tity. y= 1.12x− 22.
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same cannot be said of the Lp(a)mass assay, whichhas been reported to
be the commercially available assay least affected by apo(a) isoform size
[18]. The difference in slopes by isoform size observed in the mass vs.
particle concentration analysis (Fig. 6) illustrates this point. A conver-
sion factor of 2.4 has been recommended to convert mass values from
immunoturbidimetric assays into moles [28], but based on our ﬁndings
(Fig. 4), a factor of 3.4 is more realistic. More to the point, no single fac-
tor can be properly applied to convert mass into molar concentrations
because this conversion rests upon the assumption that the molecularFig. 4. Comparison of Lp(a)-P vs. Lp(a) mass for 1086 samples. The correlation between par
y=2.73x+ 19.7. Based on these data, a mass of 30 mg/dl would equate to amolar concentrati
molar (“particle”) concentration.mass of the particle is known, which is not the case. Variability in
Lp(a) particle mass [whether from apo(a) [18] or lipid cargo [29]] clear-
ly exists. Since a priori knowledge of themasses of each particle compo-
nent is not available in the clinical laboratory, it is impossible to
accurately convert a mass-based result into a molar concentration
(which is, by deﬁnition, directly proportional to particle concentration).
A detailed description of why this is so may be found elsewhere [25].
At the traditional risk threshold for Lp(a) mass of 30 mg/dl the cor-
responding Lp(a)-P would be about 100 nmol/l, based on the equation
in Fig. 5. Recent European guidelines [9] suggest a mass cutpoint of
N50 mg/dl, a value that would translate into an Lp(a)-P concentration
of 156 nmol/l (Fig. 4). We suggest somewhat more conservative values
of 75–125 nmol/l (intermediate risk) and N125 nmol/l (high risk) to
accommodate some of the uncertainty in the mass values (30 and
50 mg/dl) arising from the variability issues discussed above. These
cutpoints will need to be validated in future clinical trials.
Whether the prognostic value of Lp(a)-P is better than that of
Lp(a)mass for CVD also remains to be determined; however, the results
from prior studies with Lp(a) mass can most likely be extrapolated to
apply to Lp(a)-P. [5–12] In epidemiological trials, the lower molecular
mass isoforms of apo(a) are associated with higher CV risk and are con-
sidered to bemore atherogenic than the highermass isoforms. [30] This
likely reﬂects the fact that patientswith smaller apo(a) isoforms typical-
ly have higher Lp(a)-P concentrations [21]. Indeed, Hopewell et al. re-
cently reported that Lp(a)-P (estimated from a mass assay) was a
stronger predictor of coronary heart disease (CHD) risk than was
apo(a) isoform size (measured by isoelectric focusing and immunoblot-
ting) [11]. The ﬁnding that Lp(a)-P may be more predictive of CV risk
than Lp(a) mass is reminiscent of the situation with LDL, where particle
concentration appears to be a better marker of CV risk than is LDL-
cholesterol [6,26,31].
Compared to other methods for measuring Lp(a)-P, which can
require several days to perform (sample preparation by ultracentrifuga-
tion or selective precipitation followed by gradient gel electrophoresis
with immuno-probes) [32–34], with Lipo-IFE, 100 samples can be ana-
lyzed in 90 min by one technician and one instrument. Hence, it is a
cost-effective assay. There are limitations to this method, however. Inticle concentration and mass was 0.95, p b 0.001. The equation of the best-ﬁt line was
on of 101 nmol/l. Thus, at this cutpoint, a factor of 3.36xmasswould give the approximate
Y = 1.04x + 4.00
R = 0.99 
Fig. 5. Insensitivity to apo(a) isoform size. Sampleswith small (b600 kDa; n=60, red), intermediate (600–700 kDa; n=105; green), or large (N700 kDa; n=89; blue) isoform sizeswere
analyzed by the Acid Violet Lipo-IFE and by the ﬂuorescent apoB-speciﬁc antibody procedures described inMethods. The overall R between the twomethods was 0.99 (p b 0.0001), and
the slope of the regression linewas 0.99. Slopes and R by apo(a) isoform sizewere: small, 0.96 and 0.99; intermediate, 1.02, 0.98; large, 1.03 and 0.99 (not shown). These data conﬁrm that
the method is not inﬂuenced by apo(a) isoform size.
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sually examined for artifacts, and importantly, samples are damaged by a
freeze–thaw cycle and should be analyzed within 4 days of collection.
In conclusion, we have developed amethod tomeasure Lp(a)-P that
is suitable for routine clinical use. The method is precise, linear, and0
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Fig. 6. Comparison of Lipo-IFE Lp(a)-P concentrations with Lp(a) mass for samples of large (blu
formsizeswere determinedbyWestern blot analysis. Regression equations and R valueswere y
respectively. Since Fig. 5 conﬁrms that the Lipo-IFE concentration assay is not inﬂuenced by isof
by isoform size.isoform (and particle size) independent. The assay is high throughput
and relatively inexpensive to run, and thus meets the guidelines of the
European Atherosclerosis Society which recommended the use of as-
says with CVs b10% that are also economically priced and accurate [9].
Since particle concentration-based lipoprotein levels (LDL-P, HDL-P)150 200 250
ass (mg/dL)
e, n=51), intermediate (green, n=25)) and small (red, n=38) Lp(a) isoform sizes. Iso-
=1.78x+ 4.85,R= 0.89; y=1.21x+ 12.87, R= 0.96; and y=0.77x+ 68.02,R= 0.77;
orm size, the difference in slopes observed here indicates that themass assay is inﬂuenced
224 P.A. Guadagno et al. / Clinica Chimica Acta 439 (2015) 219–224have proven to be stronger predictors of risk for CV events than have li-
poprotein cholesterol-based assays, the samemay be true for Lp(a). This
hypothesis can now be readily tested using Lipo-IFE.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cca.2014.10.013.References
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